Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer and Eisai Will Continue Aricept Deal, But Add Lyrica To The Agreement

This article was originally published in PharmAsia News

Executive Summary

A potential sticking point in Pfizer's acquisition of Wyeth has been resolved - the big drug maker and Eisai have agreed to continue co-promoting Aricept (donepezil) in the U.S., Europe and Japan. However, Eisai will regain full Japanese rights to the Alzheimer's blockbuster at the end of 2012, while the rest of the collaboration will remain in place until 2022

You may also be interested in...



Eisai And Pfizer Begin Undertaking To Switch Appropriate Patients To High-dose Aricept

TOKYO - Eisai will launch a "substantial marketing campaign" behind the recent U.S. approval of high-dose Aricept (donepezil) as the company races to move moderate to severe Alzheimer's disease patients that could benefit from higher doses of the drug from the 10 mg dosage to the newly approved 23 mg dosage ahead of Aricept 10 mg's November 2010 patent loss

Eisai And Pfizer Begin Undertaking To Switch Appropriate Patients To High-dose Aricept

TOKYO - Eisai will launch a "substantial marketing campaign" behind the recent U.S. approval of high-dose Aricept (donepezil) as the company races to move moderate to severe Alzheimer's disease patients that could benefit from higher doses of the drug from the 10 mg dosage to the newly approved 23 mg dosage ahead of Aricept 10 mg's November 2010 patent loss

New Licensing Models For New Markets - BIO Conference

CHICAGO - Whether or not the world is flat, licensing deals are no longer simply a transfer of global rights, and pharma companies are trying to determine how best to carve up regional rights and how to coordinate marketing efforts

Related Content

UsernamePublicRestriction

Register

SC072870

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel